期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The clinical value of heat shock protein 90αin predicting the prognosis of interventional therapy for hepatocellular carcinoma
1
作者 孙伟 李肖 《China Medical Abstracts(Internal Medicine)》 2024年第2期108-108,共1页
Objective To evaluate the relationship between plasma heat shock protein 90α (HSP90α) level and treatment response after four weeks and long-term prognosis after transarterial chemoembolization (TACE)of hepatocellul... Objective To evaluate the relationship between plasma heat shock protein 90α (HSP90α) level and treatment response after four weeks and long-term prognosis after transarterial chemoembolization (TACE)of hepatocellular carcinoma (HCC).Methods The clinical data of HCC patients who underwent TACE in the Department of Interventional Radiology,Cancer Hospital of Chinese Academy of Medical Sciences from August 2017 to December 2018 were retrospectively collected.Chi-square tests were used to analyze the relationship between plasma HSP90α level and clinicopathological features before TACE treatment. 展开更多
关键词 HEPATOCELLULAR PROGNOSIS CLINICAL
原文传递
Analysis of the experience and procedural complications of trans-radial access versus transfemoral access forhepatic arterial perfusion chemotherapy in patients with advanced hepatic malignancies:a retrospective study
2
作者 吕天野 《China Medical Abstracts(Internal Medicine)》 2024年第2期108-109,共2页
Objective To analyze the differences between transradial access(TRA)and trans-femoral access(TFA)in hepatic arterial perfusion chemotherapy(HAIC)in terms of patient experience,postoperative complications,and patient p... Objective To analyze the differences between transradial access(TRA)and trans-femoral access(TFA)in hepatic arterial perfusion chemotherapy(HAIC)in terms of patient experience,postoperative complications,and patient preferences;explore whether TRA in HAIC is associated with better patient experience and compliance;and determine whether it is safer than TFA.Methods The study was a retrospective cohort study of patients with advanced hepatocellular carcinoma and liver metastases from colorectal cancer treated with HAIC.We enrolled a total of 91 patients with advanced liver malignancies treated with HAIC from November 2022 to May 2023 in the Department of Interventional Therapy and Hepatobiliary Medicine at Tianjin Medical University Cancer Hospital.The patients were divided into three groups:group TRA(n=20,receiving TRA HAIC only),group TFA(n=33,receiving TFA HAIC only),and crossover group[n=19,receiving TFA HAIC(Cross-TFA group)first,followed by TRA HAIC(Cross-TRA group)]. 展开更多
关键词 PATIENTS HEPATIC CHEMOTHERAPY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部